EP 3712129 A4 20201209 - ALPHA, BETA-UNSATURATED AMIDE COMPOUND
Title (en)
ALPHA, BETA-UNSATURATED AMIDE COMPOUND
Title (de)
ALPHA,BETA-UNGESÄTTIGTE AMIDVERBINDUNG
Title (fr)
COMPOSÉ AMIDE ALPHA, BETA-INSATURÉ
Publication
Application
Priority
- JP 2017123231 A 20170623
- JP 2018023723 W 20180622
Abstract (en)
[origin: EP3712129A1] An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like:[wherein, "A" represents optionally substituted heterocyclic diyl,R<sup>1</sup>represents hydrogen atom or optionally substituted lower alkyl,R<sup>2</sup>represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group,X represents -O-, -S-, -SO<sub>2</sub>-, -NR<sup>X1</sup>- (wherein, R<sup>X1</sup>represents hydrogen atom or lower alkyl), -CHR<sup>X2</sup>- (wherein, R<sup>X2</sup>represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, andn1 and n2 are the same or different, and each represents 0 or 1].
IPC 8 full level
C07D 213/75 (2006.01); A61K 31/335 (2006.01); C07D 215/20 (2006.01); C07D 215/26 (2006.01)
CPC (source: EP KR US)
A61K 31/353 (2013.01 - KR); A61K 31/47 (2013.01 - KR); A61K 31/4709 (2013.01 - KR); A61P 1/16 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 15/00 (2018.01 - EP); A61P 35/00 (2018.01 - EP KR US); C07D 213/63 (2013.01 - US); C07D 213/643 (2013.01 - US); C07D 213/75 (2013.01 - EP KR US); C07D 215/12 (2013.01 - EP KR); C07D 215/14 (2013.01 - EP); C07D 215/20 (2013.01 - EP); C07D 215/227 (2013.01 - US); C07D 215/233 (2013.01 - US); C07D 215/26 (2013.01 - EP KR US); C07D 215/36 (2013.01 - EP); C07D 215/38 (2013.01 - EP US); C07D 215/40 (2013.01 - EP KR US); C07D 217/02 (2013.01 - US); C07D 217/24 (2013.01 - EP KR); C07D 263/56 (2013.01 - EP KR US); C07D 263/57 (2013.01 - EP US); C07D 267/14 (2013.01 - EP KR US); C07D 277/64 (2013.01 - EP KR US); C07D 307/82 (2013.01 - EP KR); C07D 307/83 (2013.01 - EP US); C07D 307/86 (2013.01 - EP US); C07D 311/22 (2013.01 - EP KR); C07D 311/58 (2013.01 - EP KR US); C07D 311/64 (2013.01 - EP KR); C07D 311/68 (2013.01 - EP KR US); C07D 313/08 (2013.01 - EP KR US); C07D 333/66 (2013.01 - EP KR US); C07D 401/04 (2013.01 - EP KR US); C07D 401/12 (2013.01 - EP KR US); C07D 405/12 (2013.01 - EP KR US); C07D 413/12 (2013.01 - EP KR US); C07D 417/12 (2013.01 - EP KR); C07D 471/04 (2013.01 - EP KR US); C07D 491/052 (2013.01 - EP KR US)
Citation (search report)
No further relevant documents disclosed
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
EP 3712129 A1 20200923; EP 3712129 A4 20201209; AU 2018289759 A1 20200213; AU 2018289759 B2 20220310; CA 3068158 A1 20181227; CN 110770211 A 20200207; CN 110770211 B 20230919; JP 7221202 B2 20230213; JP WO2018235926 A1 20200521; KR 20200019979 A 20200225; SG 11201912770S A 20200130; TW 201919607 A 20190601; TW I804498 B 20230611; US 11447471 B2 20220920; US 2021155612 A1 20210527; WO 2018235926 A1 20181227
DOCDB simple family (application)
EP 18819602 A 20180622; AU 2018289759 A 20180622; CA 3068158 A 20180622; CN 201880041408 A 20180622; JP 2018023723 W 20180622; JP 2019525700 A 20180622; KR 20207001807 A 20180622; SG 11201912770S A 20180622; TW 107121407 A 20180622; US 201816625446 A 20180622